Sunday, July 31, 2022 11:57:11 AM
Could be a buy the dip opportunity
But behind the scenes it may simply be wait for fda outcome
Do you recall what proposals are on the docket for the annual meeting. That’s what matters
But behind the scenes it may simply be wait for fda outcome
Do you recall what proposals are on the docket for the annual meeting. That’s what matters
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
